The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MBIO | -90.16% | -99.94% | -77.27% | -100% |
| S&P | +12.65% | +91.73% | +13.89% | +174% |
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
The biotech announced a clinical update and an analyst initiated coverage on the stock.
A new gene therapy could be a functional cure for "bubble boy" disease.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $4.18M | -14.9% |
| Market Cap / Employee | $0.70M | 0.0% |
| Employees | 6 | -92.5% |
| Net Income | -$0.76M | 90.7% |
| EBITDA | -$0.89M | 84.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.66M | 196.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -30.39% | 140.1% |
| Return On Invested Capital | -443.64% | 105.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.34M | 42.7% |
| Operating Free Cash Flow | -$1.34M | 42.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.02 | -2.29 | -0.32 | 0.89 | -189.79% |
| Price to Tangible Book Value | -49.35 | -38.52 | -0.32 | 0.89 | -101.80% |
| Enterprise Value to EBITDA | -4.51 | -23.89 | 50.26 | 9.96 | -818.28% |
| Return on Equity | -222.4% | -322.5% | -1191.3% | - | |
| Total Debt | $0.98M | $0.88M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
